Aeolus Pharmaceuticals (AOLS) 10-K/A 13 Feb 15 2014 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Dec. 17, 2013
Document And Entity Information
Entity Registrant Name	AEOLUS PHARMACEUTICALS, INC.
Entity Central Index Key	1261734
Document Type	10-K
Document Period End Date	30-Sep-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding			0
Public Float		$0
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
ASSETS
Cash and cash equivalents	$1,517	$869
Accounts receivable	1,559	370
Deferred subcontractor cost	426	656
Prepaids and other current assets	46	39
Total current assets	3,548	1,935
Investment in CPEC LLC	32	32
Total assets	3,580	1,966
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Accounts payable and accrued expenses	1,552	579
Deferred revenue	443	682
Total current liabilities	1,995	1,261
Total liabilities	1,995	1,261
Commitments and Contingencies (Notes E and I)
Stockholders' equity (deficit):
Preferred stock, $.01 par value per share, 10,000,000 shares authorized: Series A nonredeemable convertible preferred stock, 1,250,000 shares authorized as of September 30, 2014 and 2013, respectively; no shares issued and outstanding as of September 30, 2014 and 2013, respectively	0	0
Preferred stock, $.01 par value per share, 10,000,000 shares authorized: Series B nonredeemable convertible preferred stock, 1,600,000 and 1,600,000 shares authorized as of September 30, 2014 and 2013, respectively; 526,080 and 526,080 shares issued and outstanding as of September 30, 2014 and 2013, respectively	5	5
Common stock, $.01 par value per share, 200,000,000 shares authorized; 135,850,068 and 134,550,068 shares issued and outstanding at September 30, 2014 and 2013, respectively	1,359	1,346
Additional paid-in capital	184,223	183,276
Accumulated deficit	-184,002	-183,922
Total stockholders' equity	1,585	705
Total liabilities and stockholders' equity	$3,580	$1,966

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Stockholder's deficit:
Preferred stock par value	$0.01	$0.01
Preferred stock, authorized shares	10,000,000	10,000,000
Series A nonredeemable convertible preferred stock, authorized shares	1,250,000	1,250,000
Series A nonredeemable convertible preferred stock, issued shares	0	0
Series A nonredeemable convertible preferred stock, outstanding shares	0	0
Series B nonredeemable convertible preferred stock, authorized shares	1,600,000	1,600,000
Series B nonredeemable convertible preferred stock, issued shares	526,080	526,080
Series B nonredeemable convertible preferred stock, outstanding shares	526,080	526,080
Common stock, par value	$0.01	$0.01
Common stock, Authorized	200,000,000	200,000,000
Common stock, Issued	135,850,068	134,550,068
Common stock, outstanding	135,850,068	134,550,068

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Revenue:
Contract revenue	$9,631	$3,928
Costs and expenses:
Research and development	6,966	3,360
General and administrative	2,745	3,266
Total costs and expenses	9,711	6,626
Loss from operations	-80	-2,698
Warrant liability charges	0	-510
Net loss	-80	-3,208
Net income (loss) per weighted share attributable to common stockholders - basic	-80	-3,208
Net income (loss) per weighted share attributable to common stockholders - diluted	($80)	($3,208)
Basic net loss per common share	$0	($0.03)
Diluted net loss per common share	$0	($0.03)
Weighted average common shares outstanding:
Basic	134,667	106,554
Diluted	134,667	106,554

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net income (loss)	($80)	($3,208)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	0	6
Noncash compensation	635	861
Change in fair value of warrants	0	510
Change in assets and liabilities:
Accounts receivable	-1,189	411
Deferred subcontractor cost	230	-555
Prepaid expenses and other assets	-7	16
Accounts payable and accrued expenses	973	-1,588
Deferred revenue	-239	577
Net cash provided by (used in) operating activities	323	-2,970
Cash flows from financing activities:
Proceeds from exercise of common stock warrants	325	0
Proceeds from issuance of common stock and warrants	0	3,616
Costs related to the issuance of common stock and warrants	0	-58
Net cash provided by financing activities	325	3,558
Net increase in cash and cash equivalents	648	588
Cash and cash equivalents at beginning of period	869	281
Cash and cash equivalents at end of period	$1,517	$869

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) (USD $)	Series B Preferred Stock	Common Stock [Member]	Additional Paid-In Capital	Accumulated Deficit	Total
In Thousands, except Share data
Beginning Balance - Amount at Sep. 30, 2012	$5	$627	$159,747	($180,714)	($20,335)
Beginning Balance - Shares at Sep. 30, 2012	526,080	62,731,963
Exercise of warrants, Shares		57,356,105
Exercise of warrants, Amount		574	19,255		19,829
Stock-based compensation			692		692
Issuance of warrants to consultants			169		169
Common stock sales, net of issuance costs, Shares		14,462,000
Common stock sales, net of issuance costs, Amount		145	3,413		3,558
Net income				-3,208	-3,208
Ending Balance, Amount at Sep. 30, 2013	5	1,346	183,276	-183,922	705
Ending Balance, Shares at Sep. 30, 2013	526,080	134,550,068
Exercise of warrants, Shares		1,300,000
Exercise of warrants, Amount		13	312		325
Stock-based compensation			626		626
Issuance of warrants to consultants			9		9
Net income				-80	-80
Ending Balance, Amount at Sep. 30, 2014	$5	$1,359	$184,223	($184,002)	$1,585
Ending Balance, Shares at Sep. 30, 2014	526,080	135,850,068

A_Organization_Business_and_Su

A. Organization, Business and Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
A. Organization, Business and Summary of Significant Accounting Policies	Organization
	The accompanying audited consolidated financial statements include the accounts of Aeolus Pharmaceuticals, Inc. and its wholly-owned subsidiary, Aeolus Sciences, Inc. (collectively “we,” “us,” “Company” or “Aeolus”). All significant intercompany accounts and transactions have been eliminated in consolidation.  Aeolus is a Delaware corporation. The Company’s primary operations are located in Mission Viejo, California.
	Business
	Aeolus is developing a new class of broad-spectrum, catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health.  The Company’s lead compound, 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The Company is developing 10150 as a medical countermeasure against the pulmonary effects of radiation exposure under a contract (“BARDA Contract”) valued at up to $118.4 million with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the Department of Health and Human Services (“HHS”).  Additionally, Aeolus receives development support from the National Institutes of Health (“NIH”) for development of the compound as a medical countermeasure against radiation and chemical exposure.

B_Summary_of_Significant_Accou

B. Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
B. Summary of Significant Accounting Policies	Basis of Presentation
	The consolidated financial statements include the accounts of Aeolus and its wholly owned subsidiary. All significant intercompany accounts and transactions have been eliminated. The Company uses the equity method to account for its 35.0% ownership interest in CPEC, which is further discussed in Note C.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include revenue recognition, warrant liability, allowance for doubtful accounts, stock-based compensation and warrant expense. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company invests available cash in short-term bank deposits. Cash and cash equivalents include investments with maturities of three months or less at the date of purchase. The carrying value of cash and cash equivalents approximate their fair market value at September 30, 2014 and 2013 due to their short-term nature. Also, the Company maintains cash balances with financial institutions in excess of federally insured limits. The Company does not anticipate any losses with such cash balances.
	Significant customers and accounts receivable
	For the year ended September 30, 2014, the Company’s only customer was BARDA. For the year ended September 30, 2014, revenues from BARDA comprised 100% of total revenues. As of September 30, 2014, the Company’s receivable balances were comprised 100% from this customer. Unbilled accounts receivable, included in accounts receivable, totaling $889,000 as of September 30, 2014 relate to work that has been performed, though invoicing has not yet occurred. All of the unbilled receivables are expected to be billed and collected within the next three months. Accounts receivable are stated at invoice amounts and consist primarily of amounts due from HHS as well as amounts due under reimbursement contracts with other government entities and non-government and philanthropic organizations. If necessary, the Company records a provision for doubtful receivables to allow for any amounts which may be unrecoverable. This provision is based upon an analysis of the Company’s prior collection experience, customer creditworthiness and current economic trends. As of September 30, 2014 and 2013, an allowance for doubtful accounts was not recorded as the collection history from the Company’s customers indicated that collection was probable.
	Concentrations of credit risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high quality financial institutions. Management believes that the financial risks associated with its cash and cash equivalents and investments are minimal. Because accounts receivable consist entirely of amounts due from the U.S. federal government agencies, management deems there to be minimal credit risk.
	Revenue Recognition
	Aeolus recognizes revenue in accordance with the authoritative guidance for revenue recognition.  Revenue is recognized when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery (or passage of title) has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured.
	The BARDA Contract is classified as a “cost-plus-fixed-fee” contract. Aeolus recognizes government contract revenue in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contracts. Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and indirect costs.
	Aeolus estimates subcontractor costs, materials and related revenue for some vendors when invoices are not received timely. We receive regular updates from our subcontractors regarding estimated completion of individual projects. Management evaluates the status of each project with respect to budgeted work completed, actual work completed, and cost of actual work completed. We are required to provide BARDA with monthly reports in addition to our bi-weekly conference calls with BARDA regarding the progress of each project.
	In addition, we receive a fixed fee under the BARDA Contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this BARDA Contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable.
	Fair Value of Financial Instruments
	The carrying amounts of our short-term financial instruments, which include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities.
	Fair Value Measurements
	The Company adopted Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, for financial and non-financial assets and liabilities.
	ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The Company utilizes the market approach. The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
		·	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
		·	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
		·	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
	Research and Development
	Research and development costs are expensed in the period incurred.
	Leases
	The Company leases office space and office equipment under month to month operating lease agreements. For the years ended September 30, 2014 and 2013, total rent expense was approximately $42,000 and $41,000, respectively.
	Income Taxes
	The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. A valuation allowance is established when management determines that is more likely than not that all or a portion of a deferred tax asset will not be realized. Management evaluates the Company’s ability to realize its net deferred tax assets on a quarterly basis and valuation allowances are provided, as necessary. During this evaluation, management reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the Company’s ability to realize its deferred tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. Management also applies the relevant guidance to determine the amount of income tax expense or benefit to be allocated among continuing operations, discontinued operations, and items charged or credited directly to stockholders’ equity (deficit).
	A tax position must meet a minimum probability threshold before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation process, based on the technical merits of the position. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.
	Net Income (Loss) Per Common Share
	The Company computes basic net income (loss) per weighted average share attributable to common stockholders using the weighted average number of shares of common stock outstanding during the period. The Company computes diluted net income (loss) per weighted average share attributable to common stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period. Potential common shares outstanding consist of stock options, warrants and convertible preferred stock using the treasury stock method and are excluded if their effect is anti-dilutive. Diluted weighted average common shares did not include any incremental shares for the fiscal year ended September 30, 2014 and 2013. Diluted weighted average common shares excluded incremental shares from common and preferred shares and warrants of approximately 29,048,000 and 30,517,000, respectively, for the fiscal year 2014 and 2013, due to their anti-dilutive effect.
			Fiscal Year Ended September 30,
			2014			2013
	Numerator:
	Net income (loss)		$	(80	)	$	(3,208	)
	Net income attributable to participating securities			—			—
	Net income (loss) attributable to common stockholders – basic		$	(80	)	$	(3,208	)
	Net income (loss)		$	(80	)	$	(3,208	)
	Less gain (loss) on warrant liability for participating common warrants			—			—
	Net income (loss) attributable to common stockholders – diluted		$	(80	)	$	(3,208	)
	Denominator:
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders – basic			134,667			106,554
	Effect of potentially dilutive securities:
	Common stock warrants			—			—
	Convertible preferred warrants			—			—
	Convertible preferred stock			—			—
	Common stock options			—			—
	Non-participating common stock warrants			—			—
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders – diluted			134,667			106,554
	Basic net income (loss) per common share		$	0		$	(0.03	)
	Diluted net income (loss) per common share		$	0		$	(0.03	)
	Accounting for Stock-Based Compensation
	The Company recognizes stock based compensation expense in the statement of operations based upon the fair value of the equity award amortized over the vesting period.
	Segment Reporting
	The Company currently operates in one segment.

C_Liquidity

C. Liquidity	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
C. Liquidity	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, assuming the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business.
	The Company has cash inflows and outflows from operations of approximately $323,000 and $2,970,000 for the fiscal years ended September 30, 2014 and 2013, respectively. The Company had net loss of $80,000 and $3,208,000 (including a non-cash loss for increases in valuation of warrants of $510,000) for the fiscal years ended September 30, 2014 and 2013, respectively. The Company expects to incur additional losses and cash outflows from operations for several more years.
	On May 5, 2014, the Company received a BARDA Contract Modification for $1,778,000 which reimbursed the Company for additional overhead expenses under the contract that were previously unbilled. The Contract Modification also updated our provisional indirect billing rate and placed a cap on the current and future provisional indirect billing rates. The Company estimates and accrued $304,000 in additional revenue for the fiscal year ended September 30, 2014 as a result of the new overhead rate.
	The Company has historically raised capital through the sale of its common shares and preferred shares; said financing transactions are more thoroughly discussed at note F – Stockholders’ Equity (Deficit). Management expects they will need to continue to finance the Company’s operations through equity financing for several more years.
	If the Company is unable to obtain additional funding for its operations, it will need to eliminate or substantially limit some or all of its activities, merge with another company, sell, lease or license some or all of its assets, or cease operations entirely. There is no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all, or that the Company will be able to merge with another Company or sell, lease or license any or all of its assets. This raises substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might result from this uncertainty.

D_Investments

D. Investments	12 Months Ended
	Sep. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]
D. Investments	Investment in CPEC LLC
	The Company uses the equity method to account for its 35% ownership interest in CPEC. CPEC had $91,000 of net assets at each of September 30, 2014 and 2013. Aeolus’ 35% share of CPEC’s net assets, which is approximately $32,000, is included in other assets and the Company has no operations or activities unrelated to the out licensing of bucindolol. The other 65% is owned by Endo Pharmaceuticals.

E_Commitments

E. Commitments	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
E. Commitments	The Company acquires assets still in development and enters into license and research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development life-cycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the arrangement, the Company may also be required to make royalty payments based upon a percentage of the net sales of the pharmaceutical product in the event that regulatory approval for marketing is obtained. Because of the contingent nature of these payments, they are not included in the table of contractual obligations. No milestones have been met, nor have any payments been made, as of September 30, 2014.
	We are also obligated to pay patent filing, prosecution, maintenance and defense costs, if any, for the intellectual property the Company has licensed from National Jewish Health (“NJH”), National Jewish Medical and Research Center (the “NJMRC”) and Duke University.
	These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations in any one period. In addition, these arrangements often give Aeolus the discretion to unilaterally terminate development of the product, which would allow Aeolus to avoid making the contingent payments; however, Aeolus is unlikely to cease development if the compound successfully achieves clinical testing objectives.

F_Stockholders_Equity_Deficit

F. Stockholders' Equity (Deficit)	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
F. Stockholders' Equity (Deficit)	Basis of Presentation
	Preferred Stock
	The Certificate of Incorporation of the Company authorizes the issuance of up to 10,000,000 shares of Preferred Stock, at a par value of $0.01 per share, of which 1,250,000 shares are designated Series A Convertible Preferred Stock and 1,600,000 shares are designated Series B Convertible Preferred Stock. The Board of Directors has the authority to issue Preferred Stock in one or more series, to fix the designation and number of shares of each such series, and to determine or change the designation, relative rights, preferences, and limitations of any series of Preferred Stock, without any further vote or action by the stockholders of the Company.
	As of September 30, 2014 and 2013, 526,080 shares of Series B Stock were outstanding, respectively. There are no shares of Series A Convertible Preferred Stock issued or outstanding.
	With respect to dividend rights and rights upon liquidation, winding up and dissolution, the Series B Stock ranks pari passu with the common stock. Subject to any rights of senior stock, holders of Series B Stock are entitled to receive dividends or distributions as, when and if declared by the Board of Directors. In the event the Board of Directors declares a dividend or distribution with respect to the outstanding common stock, the holders of Series B Stock are entitled to receive the amount of dividends per share in the same form payable on the common stock based on the largest number of shares of common stock issuable upon conversion of the outstanding Series B Stock. In the event of a liquidation, winding up or dissolution of the Company, subject to any rights of senior stock, the holders of Series B Stock are entitled to receive, pari passu with the holders of the common stock, the assets of the Company based on the largest number of shares of common stock issuable upon conversion of the outstanding Series B Stock.
	Each share of Series B Stock is convertible into one share of common stock. The Series B Stock can be converted into common stock at any time upon the election of the holders of the Series B Stock except to the extent such conversion would result in the holders of Series B Stock owning in the aggregate more than 9.99% of the outstanding common stock.
	The Series B Stock is not entitled to vote on any matter submitted to the vote of holders of the common stock except that the Company must obtain the approval of a majority of the outstanding shares of Series B Stock to either amend the Company’s Certificate of Incorporation in a manner that would adversely affect the Series B Stock (including by creating an additional class or series of stock with rights that are senior or pari passu to the Series B Stock) or change the rights of the holders of the Series B Stock in any other respect.
	Common Stock
	February/March 2013 Financing
	On February 19, 2013 and March 4, 2013, the Company entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain accredited investors (the “Purchasers”). Under the terms of the agreements, the Company received approximately $3,616,000 in gross proceeds in exchange for the issuance of an aggregate of 14,462,000 units (the “Units”), consisting of 14,462,000 shares of common stock and 14,462,000 warrants, at a purchase price of $0.25 per unit. Each Unit consists of (i) one share of common stock (the “Common Shares”) and (ii) a five -year warrant to purchase one share of the Company’s common stock (the “Warrants”). The Warrants have an initial exercise price of $0.25 per share.
	Net cash proceeds from the February/March 2013 Financing, after deducting for $58,000 of expenses, were approximately $3,558,000. The Company also incurred non-cash expenses in the form of 365,000 warrants issued to consultants, at similar terms as the financing Warrants, for services provided. The Company issued a total of 14,827,000 warrants in connection with the February/March 2013 Financing.
	The fair value of the February/March 2013 Financing warrants was estimated to be $4,791,000 using the Black-Scholes option pricing model with the following assumptions: dividend yield of 0%, expected volatility of 154.84%, risk free interest rate of 0.87% and an expected life of five years. The proceeds from the February/March 2013 Financing were allocated based upon the relative fair values of the February/March 2013 Financing Warrants and the February/March 2013 Common Shares.
	The February/March 2013 Financing contains a registration rights agreement with an arrangement for liquidated damages in the event of a failure to maintain the effectiveness with the SEC of a registration statement covering the February/March 2013 Financing Units. The Company must use its commercially reasonable to maintain the registration statement continuously effective until the earlier to occur of (i) the date on which all securities covered by such registration statement have been sold, and (ii) the date on which all securities covered by such registration statement may be sold without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended. In the event the Company fails to meet this obligation, subject to certain exceptions, the Company will be required to make a cash payment of 0.5% of the aggregate amount invested to the Purchasers of the February/March 2013 Financing Units. The 0.5% payment equaling $18,000 would be due for every 30-day period in which the registration statement is not continuously effective. The maximum liability would be $108,000 and no damages would accrue after August 19, 2013, the date that is six months from the closing of the February/March 2013 Financing.  The registration statement was declared effective by the SEC as of June 13, 2013.
	Modification to rights of Security Holders
	Effective February 19, 2013, the Company and each of Xmark JV Investment Partners, LLC, Xmark Opportunity Fund, Ltd. and Xmark Opportunity Fund, L.P. (collectively, the “Xmark Entities”) entered into a Warrant Repricing, Exercise and Lockup Agreement (the “Xmark Warrant Agreement”) pursuant to which the Company agreed to reduce the exercise price of outstanding warrants to purchase an aggregate of up to 59,149,999 shares of Common Stock held by the Xmark Entities (the “Xmark Warrants”) to $0.01 per share. In consideration for the reduction of the exercise price of the Xmark Warrants, each of the Xmark Entities agreed to immediately exercise all of the Xmark Warrants by cashless exercise. The Xmark Warrant Agreement also provides that the Xmark Entities will not transfer the shares issuable upon exercise of the Xmark Warrants (the “Xmark Warrant Shares”) until the Company either (i) declares a cash dividend on its common stock or otherwise makes a cash distribution or (ii) effects a Change of Control, subject in each case to the terms of the Xmark Warrant Agreement.
	Modifying the exercise price of the warrants to a fixed amount of $0.01 eliminated the requirement for warrant liability accounting treatment and resulted in a charge of $2,084,000.
	Dividends
	The Company has never paid a cash dividend on its common stock and does not anticipate paying cash dividends on its common stock in the foreseeable future. If we pay a cash dividend on our common stock, we also must pay the same dividend on an as converted basis on our Series B preferred stock.
	Warrants
	As of September 30, 2014, warrants to purchase an aggregate of 16,029,627 shares of common stock were outstanding. Details of the warrants for common stock outstanding at September 30, 2014 were as follows:
		Number of Shares			Exercise Price			Expiration Date
			50,000		$	0.38		Apr-15
			50,000		$	0.5		May-16
			50,000		$	0.5		Jul-16
			50,000		$	1		Jul-16
			50,000		$	1.5		Jul-16
			50,000		$	2		Jul-16
			50,000		$	2.5		Jul-16
			1,337,627		$	0.40		Mar-17
			325,000		$	0.40		Apr-17
			300,000		$	0.258		Jun-17
			50,000		$	0.26		Jun-17
			140,000		$	0.35		Oct-17
			12,285,000		$	0.25		Feb-18
			1,242,000		$	0.25		Mar-18
			16,029,627
	As of September 30, 2014, one warrant to purchase an aggregate of 896,037 shares of preferred stock was outstanding.
	As of September 30, 2013, warrants to purchase an aggregate of 17,879,627 shares of common stock were outstanding. Details of the warrants for common stock outstanding at September 30, 2013 were as follows:
		Number of Shares				Exercise Price			Expiration Date
			100,000			$	0.50		May-14
			100,000			$	1		May-14
			100,000			$	1.5		May-14
			125,000			$	0.51		Jun-14
			125,000			$	1		Jun-14
			20,000			$	0.39		Sep-14
			15,000			$	0.50		Sep-14
			15,000			$	0.60		Sep-14
			50,000			$	0.38		Apr-15
			50,000			$	0.5		May-16
			50,000			$	0.5		Jul-16
			50,000			$	1		Jul-16
			50,000			$	1.5		Jul-16
			50,000			$	2		Jul-16
			50,000			$	2.5		Jul-16
			1,337,627			$	0.40		Mar-17
			325,000			$	0.40		Apr-17
			300,000			$	0.258		Jun-17
			140,000			$	0.35		Oct-17
			13,085,000			$	0.25		Feb-18
			1,742,000			$	0.25		Mar-18
			17,879,627
	As of September 30, 2013, one warrant to purchase an aggregate of 896,037 shares of preferred stock was outstanding.
	Below is a summary of warrant activity for the last two fiscal years ended September 30:
							Weighted Average
									Remaining	Aggregate
		Number				Exercise			Contractual	Intrinsic
		of Shares				Price			Term (in years)	Value
Outstanding at 9/30/2012			62,993,663			$	0.3		4.2 years	$	5,344
Granted			14,932,000			$	0.25		4.4 years	$	444,810
Exercised			(59,149,999	)		$	0.01			$	19,519,500
Cancelled			-			$	-			$	-
Forfeited			-			$	-			$	-
Outstanding at 9/30/2013			18,775,664			$	0.29		4.1 years	$	693,340
Granted			50,000			$	0.26			$	-
Exercised			(1,300,000	)		$	0.25			$	318,000
Cancelled			(600,000	)		$	0.86			$	-
Forfeited			-			$	-			$	-
Outstanding at 9/30/2014			16,925,664			$	0.27		3.1 years	$	215,048
Exercisable at 9/30/2014			16,925,664			$	0.27		3.1 years	$	215,048

G_StockBased_Compensation

G. Stock-Based Compensation	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
G. Stock-Based Compensation	As an integral component of a management and employee retention program designed to motivate, retain and provide incentive to the Company’s management, employees and key consultants, the Board of Directors approved the 2004 Stock Incentive Plan (the “2004 Plan”) and reserved 25,000,000 shares of common stock for issuance under the 2004 Plan. As of September 30, 2014, 13,405,909 shares were available to be granted under the 2004 Plan. The exercise price of the incentive stock options (“ISOs”) granted under the 2004 Plan must not be less than the fair market value of the common stock as determined on the date of the grant. The options may have a term up to 10 years. Options typically vest immediately or up to one year following the date of the grant.
	Under the Company’s 1994 Stock Option Plan (the “1994 Plan”), incentive stock options or non-qualified stock options to purchase 2,500,000 shares of Aeolus’ common stock may be granted to employees, directors and consultants of the Company. As of September 30, 2014, there were no shares available to be granted under the 1994 Plan. The exercise price of the ISOs granted under the 1994 Plan must not be less than the fair market value of the common stock as determined on the date of the grant. The options may have a term up to 10 years. Options typically vest over one to three years following the date of the grant.
	Below is a summary of stock option activity for the last three fiscal years ended September 30:
						Weighted Average
										Remaining			Aggregate
			Number				Exercise			Contractual			Intrinsic
			of Shares				Price			Term (in years)			Value
	Outstanding at 9/30/2012		9,473,661			$	0.7			5.8 years		$	154
	Granted		3,070,000			$	0.4			9.4 years		$	—
	Exercised		—			$	—					$	—
	Cancelled		(1,328,763	)		$	1.46					$	—
	Forfeited		—			$	—					$	—
	Outstanding at 9/30/2013		11,214,898			$	0.52			6.7 years		$	2
	Granted		775,000			$	0.26					$	—
	Exercised		—			$	—					$	—
	Cancelled		(393,307	)		$	2.64					$	—
	Forfeited		—			$	—					$	—
	Outstanding at 9/30/2014		11,596,591			$	0.43			6.1 years		$	1
	Exercisable at 9/30/2014		11,427,839			$	0.44			6.1 years		$	1
	Stock options granted to consultants during fiscal year 2014 and 2013 were fully vested when issued or vested over a twelve month period. Stock option expense for stock options granted to consultants was $11,000 and $20,000 for fiscal year 2014 and 2013, respectively. For the fiscal years 2014 and 2013, all stock options were issued at or above fair market value of a share of common stock. The weighted-average grant-date fair value of options granted during fiscal years 2014 and 2013 was $0.26 and $0.40, respectively.
	A summary of the status of non-vested shares for the fiscal years ended September 30 was:
						Weighted Average
		Number				Grant-Date
		of Shares				Fair Value
	Nonvested at September 30, 2012		406,766			$	0.26
	Granted		3,070,000			$	0.37
	Vested		(1,994,480	)		$	0.34
	Forfeited		-			$	-
	Nonvested at September 30, 2013		1,482,286			$	0.37
	Granted		775,000			$	0.22
	Vested		(2,088,534	)		$	0.33
	Forfeited		-			$	-
	Nonvested at September 30, 2014		168,752			$	0.22
	The total unrecognized compensation expense for outstanding stock options was $172,000 as of September 30, 2014, which will be recognized over a weighted average period of five months. The total fair value of shares vested during fiscal years 2014 and 2013 was $688,000 and $687,000, respectively.
	The details of stock options for the fiscal year ended September 30, 2014 are as follows:
				Options Outstanding									Options Exercisable
											Weighted					Weighted
				Number				Weighted			Average		Number	Weighted		Average
	Range of			Outstanding at				Average			Remaining		Exercisable at	Average		Remaining
	Exercise			September 30,				Exercise			Contractual		September 30,	Exercise		Contractual
	Prices			2014				Price			Life (in years)		2014	Price		Life (in years)
	$0.23-$0.30				2,387,500			$	0.28		6.55		2,218,748	$	0.28	6.34
	$0.31-$0.40				6,501,500			$	0.39		6.82		6,501,500	$	0.39	6.82
	$0.41-$0.50				502,000			$	0.45		7.25		502,000	$	0.45	7.25
	$0.51-$0.60				963,750			$	0.59		4.64		963,750	$	0.59	4.64
	$0.61-$0.70				66,500			$	0.68		1.88		66,500	$	0.68	1.88
	$0.71-$0.80				382,250			$	0.75		2.66		382,250	$	0.75	2.66
	$0.81-$0.90				697,091			$	0.88		2.01		697,091	$	0.88	2.01
	$0.91-$1.00				44,500			$	0.94		0.99		44,500	$	0.94	0.99
	$1.01-$1.45				51,500			$	1.13		1.01		51,500	$	1.13	1.01
					11,596,591			$	0.43		6.1		11,427,839	$	0.44	6.05
	Stock-based compensation expense recognized in the statement of operations is as follows (in thousands):
		For the fiscal year ended September 30,
		2014				2013
	Research and Development Expenses	$	11			$	20
	General and Administrative Expenses		624				841
	Total Stock-based Compensation Expense	$	635			$	861
	The fair value of the options associated with the above compensation expense was determined at the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions:
		For the fiscal year ended September 30,
		2014				2013
	Dividend yield		0	%			0	%
	Expected volatility		122	%			156	%
	Risk-free interest rate		1.54	%			0.86	%
	Expected option life after shares are vested	5.27 years				5.27 years

H_Income_Taxes

H. Income Taxes	12 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]
H. Income Taxes
	As of September 30, 2014 and 2013, the Company had federal net operating loss (“NOL”) carry-forwards of $113,321,000 and $113,091,000, respectively and state operating loss carry-forwards of $35,244,000 and $35,016,000, respectively. The use of these federal and state NOL carry-forwards might be subject to limitation under the rules regarding a change in stock ownership as determined by the Internal Revenue Code (the “Code”). The Company may have had a change of control under Section 382 of the Code during fiscal 2004 and 2006; however, a complete analysis of the limitation of the NOL carry-forwards will not be completed until the time the Company projects it will be able to utilize such NOLs. The federal net operating and the state net operating losses began to expire in 2010. Additionally, the Company had federal research and development carry-forwards as of September 30, 2014 and 2013 of $3,990,000 and $3,714,000, respectively. The Company had state research and development carry-forwards as of September 30, 2014 and 2013 of $1,316,000 and $1,033,000, respectively.
	Significant components of the Company’s deferred tax assets at September 30, 2014 and 2013 consisted of the following (in thousands):
		2014			2013
	Accrued payroll related liabilities	$	1,103		$	915
	Depreciation and amortization		704			823
	State Taxes		-126			(121	)
	Total deferred tax assets		1,681			1,617
	Deferred tax liabilities		—			—
	Valuation allowance for deferred assets		(1,681	)		(1,617	)
	Net deferred tax asset	$	—		$	—
	Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, all of the deferred tax assets have been fully offset by a valuation allowance. The change in the valuation allowance is primarily a result of the net operating loss carry-forwards.
	Taxes computed at the statutory federal income tax rate of 34% are reconciled to the provision for income taxes as follows (dollars in thousands):
		2014			2013
	Effective income tax rate		0	%		0	%
	United States Federal income tax at statutory rate	$	(25	)	$	(1,091	)
	State income taxes (net of federal benefit)		1			5
	Warrant expense		—			173
	Prior year deferred true up		(280	)		(1,684	)
	Change in valuation reserves		96			(1,863	)
	FIN 48		354			4,396
	Other		(144	)		66
	Provision for income taxes	$	2		$	2
	At September 30, 2014, we had unrecognized tax benefits of $4,859,000, all of which would impact the effective tax rate if recognized, however a valuation allowance would be recorded against this amount.  During Fiscal 2013, unrecognized tax benefits increased to $4,401,000 as a result of the tax positions taken in prior years and current year.  No interest and penalties have been provided for with respect to the unrecognized tax benefits.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
		Amount
		(in thousands)
	Unrecognized tax benefits at October 1, 2013	$	4,397
	Additions for tax positions related to current year		458
	Additions/reductions for tax positions taken in prior years		4
	Settlements		-
	Lapse of Limitations		-
	Unrecognized tax benefits at September 30, 2014	$	4,859
	The Company’s federal income tax returns for the tax years 2010 to 2012 remain open to examination. The Company’s California income tax returns for the tax years 2009 to 2012 remain open to examination.

I_Contingencies

I. Contingencies	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
I. Contingencies	Duke Licenses
	The Company has obtained exclusive worldwide licenses (the “Duke Licenses”) from Duke University (“Duke”) to develop, make, have made, use and sell products using certain technology in the field of free radical and antioxidant research, developed by certain scientists at Duke. Future discoveries in the field of antioxidant research from these scientists’ laboratories at Duke are also covered by the Duke Licenses. The Duke Licenses require the Company to use its best efforts to pursue development of products using the licensed technology and compounds. These efforts are to include the manufacture or production of products for testing, development and sale. Aeolus is also obligated to use its best efforts to have the licensed technology cleared for marketing in the United States by the U.S. Food and Drug Administration and in other countries in which Aeolus intends to sell products using the licensed technology. Aeolus will pay royalties to Duke on net product sales during the terms of the Duke Licenses, and milestone payments upon certain regulatory approvals and annual sales levels. In addition, Aeolus is obligated under the Duke Licenses to pay all or a portion of patent prosecution, maintenance and defense costs. Unless earlier terminated, the Duke Licenses continue until the expiration of the last to expire issued patent on the licensed technology.
	National Jewish Medical and Research Center Agreements
	Aeolus has an exclusive worldwide license (“NJH License”) from National Jewish Health to develop, make, have made, use and sell products using certain technology developed by certain scientists at NJH. The NJH License requires Aeolus to use commercially reasonable efforts to diligently pursue the development and government approval of products using the licensed technology. Aeolus will be obligated to pay royalties to NJH on net product sales during the term of the NJH License and a milestone payment upon regulatory approval, if obtained. In addition, Aeolus is obligated under the NJH License to pay all or a portion of patent prosecution, maintenance and defense costs. Unless earlier terminated, the NJH License continues until the expiration of the last to expire issued patent on the licensed technology.

J_Agreements

J. Agreements	12 Months Ended
	Sep. 30, 2014
Notes to Financial Statements
J. Agreements	Elan Corporation, plc
	In May 2002, the Company entered into a collaboration transaction with affiliates of Elan Corporation, plc for the development of the Company’s catalytic antioxidant compounds as a treatment for tissue damage from cancer radiation and chemotherapy. Although Elan and the Company terminated this collaboration in January 2003, the Company will pay Elan a royalty on net sales of its catalytic antioxidant products sold, if any, for the prevention and treatment of radiation-induced and chemotherapy-induced tissue damage.

K_Litigation

K. Litigation	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
K. Litigation	From time to time we are subject to various lawsuits and claims with respect to matters arising out of the normal course of our business. Due to the uncertainty of the ultimate outcome of these matters, the impact on future financial results is not subject to reasonable estimates.

L_Quarterly_Financial_Data_una

L. Quarterly Financial Data (unaudited)	12 Months Ended
	Sep. 30, 2014
Quarterly Financial Information Disclosure [Abstract]
J. Quarterly Financial Data (unaudited)		First			Second			Third			Fourth			Total
		Quarter			Quarter			Quarter			Quarter			Year
		(in thousands, except per share amounts)
	Fiscal 2014
	Total revenue	$	793		$	1,438		$	4,983		$	2,417		$	9,631
	Net income (loss)	$	(695	)	$	(437	)	$	1,576		$	(524	)	$	(80	)
	Net income available to stockholders – Basic	$	(695	)	$	(437	)	$	1,576		$	(524	)	$	(80	)
	Net income available to stockholders – Diluted	$	(695	)	$	(437	)	$	1,576		$	(524	)	$	(80	)
	Basic net income (loss) per common share attributable to common stockholders	$	(0.01	)	$	0		$	0.01		$	0		$	0
	Diluted net income (loss) per common share attributable to common stockholders	$	(0.01	)	$	0		$	0.01		$	0		$	0
	Fiscal 2013
	Total revenue	$	1,342		$	859		$	844		$	883		$	3,928
	Net income (loss)	$	4,028		$	(5,782	)	$	(786	)	$	(668	)	$	(3,208	)
	Net income available to stockholders – Basic	$	2,049		$	(5,782	)	$	(786	)	$	(668	)	$	(3,208	)
	Net income available to stockholders – Diluted	$	(200	)	$	(5,782	)	$	(786	)	$	(668	)	$	(3,208	)
	Basic net income (loss) per common share attributable to common stockholders	$	0.03		$	(0.06	)	$	(0.01	)	$	0		$	(0.03	)
	Diluted net income (loss) per common share attributable to common stockholders	$	0		$	(0.06	)	$	(0.01	)	$	0		$	(0.03	)

B_Organization_Business_and_Su

B. Organization, Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2014
B. Organization Business And Summary Of Significant Accounting Policies Policies
Organization	The accompanying audited consolidated financial statements include the accounts of Aeolus Pharmaceuticals, Inc. and its wholly-owned subsidiary, Aeolus Sciences, Inc. (collectively “we,” “us,” “Company” or “Aeolus”). All significant intercompany accounts and transactions have been eliminated in consolidation.  Aeolus is a Delaware corporation. The Company’s primary operations are located in Mission Viejo, California.
Business	Aeolus is developing a new class of broad-spectrum, catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health.  The Company’s lead compound, 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The Company is developing 10150 as a medical countermeasure against the pulmonary effects of radiation exposure under a contract (“BARDA Contract”) valued at up to $118.4 million with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the Department of Health and Human Services (“HHS”).  Additionally, Aeolus receives development support from the National Institutes of Health (“NIH”) for development of the compound as a medical countermeasure against radiation and chemical exposure.
Basis of Presentation	The consolidated financial statements include the accounts of Aeolus and its wholly owned subsidiary. All significant intercompany accounts and transactions have been eliminated. The Company uses the equity method to account for its 35.0% ownership interest in CPEC, which is further discussed in Note C.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include revenue recognition, warrant liability, allowance for doubtful accounts, stock-based compensation and warrant expense. Actual results could differ from those estimates.
Cash and Cash Equivalents	The Company invests available cash in short-term bank deposits. Cash and cash equivalents include investments with maturities of three months or less at the date of purchase. The carrying value of cash and cash equivalents approximate their fair market value at September 30, 2014 and 2013 due to their short-term nature. Also, the Company maintains cash balances with financial institutions in excess of federally insured limits. The Company does not anticipate any losses with such cash balances.
Significant customer and accounts receivable	For the year ended September 30, 2014, the Company’s only customer was BARDA. For the year ended September 30, 2014, revenues from BARDA comprised 100% of total revenues. As of September 30, 2014, the Company’s receivable balances were comprised 100% from this customer. Unbilled accounts receivable, included in accounts receivable, totaling $889,000 as of September 30, 2014 relate to work that has been performed, though invoicing has not yet occurred. All of the unbilled receivables are expected to be billed and collected within the next three months. Accounts receivable are stated at invoice amounts and consist primarily of amounts due from HHS as well as amounts due under reimbursement contracts with other government entities and non-government and philanthropic organizations. If necessary, the Company records a provision for doubtful receivables to allow for any amounts which may be unrecoverable. This provision is based upon an analysis of the Company’s prior collection experience, customer creditworthiness and current economic trends. As of September 30, 2014 and 2013, an allowance for doubtful accounts was not recorded as the collection history from the Company’s customers indicated that collection was probable.
Concentrations of credit risk	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high quality financial institutions. Management believes that the financial risks associated with its cash and cash equivalents and investments are minimal. Because accounts receivable consist entirely of amounts due from the U.S. federal government agencies, management deems there to be minimal credit risk.
Revenue Recognition	Aeolus recognizes revenue in accordance with the authoritative guidance for revenue recognition.  Revenue is recognized when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery (or passage of title) has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured.
	The BARDA Contract is classified as a “cost-plus-fixed-fee” contract. Aeolus recognizes government contract revenue in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contracts. Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and indirect costs.
	Aeolus estimates subcontractor costs, materials and related revenue for some vendors when invoices are not received timely. We receive regular updates from our subcontractors regarding estimated completion of individual projects. Management evaluates the status of each project with respect to budgeted work completed, actual work completed, and cost of actual work completed. We are required to provide BARDA with monthly reports in addition to our bi-weekly conference calls with BARDA regarding the progress of each project.
	In addition, we receive a fixed fee under the BARDA Contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this BARDA Contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable.
Fair Value of Financial Instruments	The carrying amounts of our short-term financial instruments, which include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate their fair values due to their short maturities.
Fair Value Measurements	ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The Company utilizes the market approach. The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
		·	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
		·	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
		·	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
Research and Development	Research and development costs are expensed in the period incurred.
Leases	The Company leases office space and office equipment under month to month operating lease agreements. For the years ended September 30, 2014 and 2013, total rent expense was approximately $42,000 and $41,000, respectively.
Income Taxes	The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. A valuation allowance is established when management determines that is more likely than not that all or a portion of a deferred tax asset will not be realized. Management evaluates the Company’s ability to realize its net deferred tax assets on a quarterly basis and valuation allowances are provided, as necessary. During this evaluation, management reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the Company’s ability to realize its deferred tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. Management also applies the relevant guidance to determine the amount of income tax expense or benefit to be allocated among continuing operations, discontinued operations, and items charged or credited directly to stockholders’ equity (deficit).
	A tax position must meet a minimum probability threshold before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation process, based on the technical merits of the position. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.
Net Income (Loss) Per Common Share	The Company computes basic net income (loss) per weighted average share attributable to common stockholders using the weighted average number of shares of common stock outstanding during the period. The Company computes diluted net income (loss) per weighted average share attributable to common stockholders using the weighted average number of shares of common and dilutive potential common shares outstanding during the period. Potential common shares outstanding consist of stock options, warrants and convertible preferred stock using the treasury stock method and are excluded if their effect is anti-dilutive. Diluted weighted average common shares did not include any incremental shares for the fiscal year ended September 30, 2014 and 2013. Diluted weighted average common shares excluded incremental shares from common and preferred shares and warrants of approximately 29,048,000 and 30,517,000, respectively, for the fiscal year 2014 and 2013, due to their anti-dilutive effect.
			Fiscal Year Ended September 30,
			2014			2013
	Numerator:
	Net income (loss)		$	(80	)	$	(3,208	)
	Net income attributable to participating securities			—			—
	Net income (loss) attributable to common stockholders – basic		$	(80	)	$	(3,208	)
	Net income (loss)		$	(80	)	$	(3,208	)
	Less gain (loss) on warrant liability for participating common warrants			—			—
	Net income (loss) attributable to common stockholders – diluted		$	(80	)	$	(3,208	)
	Denominator:
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders – basic			134,667			106,554
	Effect of potentially dilutive securities:
	Common stock warrants			—			—
	Convertible preferred warrants			—			—
	Convertible preferred stock			—			—
	Common stock options			—			—
	Non-participating common stock warrants			—			—
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders – diluted			134,667			106,554
	Basic net income (loss) per common share		$	0		$	(0.03	)
	Diluted net income (loss) per common share		$	0		$	(0.03	)
Accounting for Stock-Based Compensation	The Company recognizes stock based compensation expense in the statement of operations based upon the fair value of the equity award amortized over the vesting period.
Segment Reporting	The Company currently operates in one segment.

B_Organization_Business_and_Su1

B. Organization, Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2014
B. Organization Business And Summary Of Significant Accounting Policies Tables
Schedule of Earnings Per Share, Basic and Diluted		Fiscal Year Ended September 30,
		2014			2013
	Numerator:
	Net income (loss)	$	(80	)	$	(3,208	)
	Net income attributable to participating securities		—			—
	Net income (loss) attributable to common stockholders – basic	$	(80	)	$	(3,208	)
	Net income (loss)	$	(80	)	$	(3,208	)
	Less gain (loss) on warrant liability for participating common warrants		—			—
	Net income (loss) attributable to common stockholders – diluted	$	(80	)	$	(3,208	)
	Denominator:
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders – basic		134,667			106,554
	Effect of potentially dilutive securities:
	Common stock warrants		—			—
	Convertible preferred warrants		—			—
	Convertible preferred stock		—			—
	Common stock options		—			—
	Non-participating common stock warrants		—			—
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders – diluted		134,667			106,554
	Basic net income (loss) per common share	$	0		$	(0.03	)
	Diluted net income (loss) per common share	$	0		$	(0.03	)

F_Stockholders_Equity_Tables

F. Stockholder's Equity (Tables)	12 Months Ended
	Sep. 30, 2014
F. Stockholders Equity Tables
Warrants for Common Stock Outstanding	As of September 30, 2014, warrants to purchase an aggregate of 16,029,627 shares of common stock were outstanding. Details of the warrants for common stock outstanding at September 30, 2014 were as follows:
		Number of Shares			Exercise Price			Expiration Date
			50,000		$	0.38		Apr-15
			50,000		$	0.5		May-16
			50,000		$	0.5		Jul-16
			50,000		$	1		Jul-16
			50,000		$	1.5		Jul-16
			50,000		$	2		Jul-16
			50,000		$	2.5		Jul-16
			1,337,627		$	0.40		Mar-17
			325,000		$	0.40		Apr-17
			300,000		$	0.258		Jun-17
			50,000		$	0.26		Jun-17
			140,000		$	0.35		Oct-17
			12,285,000		$	0.25		Feb-18
			1,242,000		$	0.25		Mar-18
			16,029,627
	As of September 30, 2013, warrants to purchase an aggregate of 17,879,627 shares of common stock were outstanding. Details of the warrants for common stock outstanding at September 30, 2013 were as follows:
		Number of Shares				Exercise Price			Expiration Date
			100,000			$	0.50		May-14
			100,000			$	1		May-14
			100,000			$	1.5		May-14
			125,000			$	0.51		Jun-14
			125,000			$	1		Jun-14
			20,000			$	0.39		Sep-14
			15,000			$	0.50		Sep-14
			15,000			$	0.60		Sep-14
			50,000			$	0.38		Apr-15
			50,000			$	0.5		May-16
			50,000			$	0.5		Jul-16
			50,000			$	1		Jul-16
			50,000			$	1.5		Jul-16
			50,000			$	2		Jul-16
			50,000			$	2.5		Jul-16
			1,337,627			$	0.40		Mar-17
			325,000			$	0.40		Apr-17
			300,000			$	0.258		Jun-17
			140,000			$	0.35		Oct-17
			13,085,000			$	0.25		Feb-18
			1,742,000			$	0.25		Mar-18
			17,879,627
Summary Of Warrant Activity							Weighted Average
										Remaining	Aggregate
			Number				Exercise			Contractual	Intrinsic
			of Shares				Price			Term (in years)	Value
	Outstanding at 9/30/2012			62,993,663			$	0.3		4.2 years	$	5,344
	Granted			14,932,000			$	0.25		4.4 years	$	444,810
	Exercised			(59,149,999	)		$	0.01			$	19,519,500
	Cancelled			-			$	-			$	-
	Forfeited			-			$	-			$	-
	Outstanding at 9/30/2013			18,775,664			$	0.29		4.1 years	$	693,340
	Granted			50,000			$	0.26			$	-
	Exercised			(1,300,000	)		$	0.25			$	318,000
	Cancelled			(600,000	)		$	0.86			$	-
	Forfeited			-			$	-			$	-
	Outstanding at 9/30/2014			16,925,664			$	0.27		3.1 years	$	215,048
	Exercisable at 9/30/2014			16,925,664			$	0.27		3.1 years	$	215,048

G_StockBased_Compensation_Tabl

G. Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2014
G. Stock-Based Compensation Tables
Summary Of Stock Option Activity						Weighted Average
										Remaining			Aggregate
			Number				Exercise			Contractual			Intrinsic
			of Shares				Price			Term (in years)			Value
	Outstanding at 9/30/2012		9,473,661			$	0.7			5.8 years		$	154
	Granted		3,070,000			$	0.4			9.4 years		$	—
	Exercised		—			$	—					$	—
	Cancelled		(1,328,763	)		$	1.46					$	—
	Forfeited		—			$	—					$	—
	Outstanding at 9/30/2013		11,214,898			$	0.52			6.7 years		$	2
	Granted		775,000			$	0.26					$	—
	Exercised		—			$	—					$	—
	Cancelled		(393,307	)		$	2.64					$	—
	Forfeited		—			$	—					$	—
	Outstanding at 9/30/2014		11,596,591			$	0.43			6.1 years		$	1
	Exercisable at 9/30/2014		11,427,839			$	0.44			6.1 years		$	1
Schedule of non-vested shares						Weighted Average
		Number				Grant-Date
		of Shares				Fair Value
	Nonvested at September 30, 2012		406,766			$	0.26
	Granted		3,070,000			$	0.37
	Vested		(1,994,480	)		$	0.34
	Forfeited		-			$	-
	Nonvested at September 30, 2013		1,482,286			$	0.37
	Granted		775,000			$	0.22
	Vested		(2,088,534	)		$	0.33
	Forfeited		-			$	-
	Nonvested at September 30, 2014		168,752			$	0.22
Details Of Stock Options				Options Outstanding									Options Exercisable
											Weighted					Weighted
				Number				Weighted			Average		Number	Weighted		Average
	Range of			Outstanding at				Average			Remaining		Exercisable at	Average		Remaining
	Exercise			September 30,				Exercise			Contractual		September 30,	Exercise		Contractual
	Prices			2014				Price			Life (in years)		2014	Price		Life (in years)
	$0.23-$0.30				2,387,500			$	0.28		6.55		2,218,748	$	0.28	6.34
	$0.31-$0.40				6,501,500			$	0.39		6.82		6,501,500	$	0.39	6.82
	$0.41-$0.50				502,000			$	0.45		7.25		502,000	$	0.45	7.25
	$0.51-$0.60				963,750			$	0.59		4.64		963,750	$	0.59	4.64
	$0.61-$0.70				66,500			$	0.68		1.88		66,500	$	0.68	1.88
	$0.71-$0.80				382,250			$	0.75		2.66		382,250	$	0.75	2.66
	$0.81-$0.90				697,091			$	0.88		2.01		697,091	$	0.88	2.01
	$0.91-$1.00				44,500			$	0.94		0.99		44,500	$	0.94	0.99
	$1.01-$1.45				51,500			$	1.13		1.01		51,500	$	1.13	1.01
					11,596,591			$	0.43		6.1		11,427,839	$	0.44	6.05
Stock-based compensation expense		For the fiscal year ended September 30,
		2014				2013
	Research and Development Expenses	$	11			$	20
	General and Administrative Expenses		624				841
	Total Stock-based Compensation Expense	$	635			$	861
Assumptions Of Stock Based Compensation		For the fiscal year ended September 30,
		2014				2013
	Dividend yield		0	%			0	%
	Expected volatility		122	%			156	%
	Risk-free interest rate		1.54	%			0.86	%
	Expected option life after shares are vested	5.27 years				5.27 years

H_Income_Taxes_Tables

H. Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2014
H. Income Taxes Tables
Deferred tax assets
		2014			2013
	Accrued payroll related liabilities	$	1,103		$	915
	Depreciation and amortization		704			823
	State Taxes		-126			(121	)
	Total deferred tax assets		1,681			1,617
	Deferred tax liabilities		—			—
	Valuation allowance for deferred assets		(1,681	)		(1,617	)
	Net deferred tax asset	$	—		$	—
Tax rate reconciliation
		2014			2013
	Effective income tax rate		0	%		0	%
	United States Federal income tax at statutory rate	$	(25	)	$	(1,091	)
	State income taxes (net of federal benefit)		1			5
	Warrant expense		—			173
	Prior year deferred true up		(280	)		(1,684	)
	Change in valuation reserves		96			(1,863	)
	FIN 48		354			4,396
	Other		(144	)		66
	Provision for income taxes	$	2		$	2
Unrecognized tax benefits		Amount
		(in thousands)
	Unrecognized tax benefits at October 1, 2013	$	4,397
	Additions for tax positions related to current year		458
	Additions/reductions for tax positions taken in prior years		4
	Settlements		-
	Lapse of Limitations		-
	Unrecognized tax benefits at September 30, 2014	$	4,859

J_Quarterly_Financial_Data_una

J. Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Sep. 30, 2014
J. Quarterly Financial Data Tables
Quarterly Financial Data		First			Second			Third			Fourth			Total
		Quarter			Quarter			Quarter			Quarter			Year
		(in thousands, except per share amounts)
	Fiscal 2014
	Total revenue	$	793		$	1,438		$	4,983		$	2,417		$	9,631
	Net income (loss)	$	(695	)	$	(437	)	$	1,576		$	(524	)	$	(80	)
	Net income available to stockholders – Basic	$	(695	)	$	(437	)	$	1,576		$	(524	)	$	(80	)
	Net income available to stockholders – Diluted	$	(695	)	$	(437	)	$	1,576		$	(524	)	$	(80	)
	Basic net income (loss) per common share attributable to common stockholders	$	(0.01	)	$	0		$	0.01		$	0		$	0
	Diluted net income (loss) per common share attributable to common stockholders	$	(0.01	)	$	0		$	0.01		$	0		$	0
	Fiscal 2013
	Total revenue	$	1,342		$	859		$	844		$	883		$	3,928
	Net income (loss)	$	4,028		$	(5,782	)	$	(786	)	$	(668	)	$	(3,208	)
	Net income available to stockholders – Basic	$	2,049		$	(5,782	)	$	(786	)	$	(668	)	$	(3,208	)
	Net income available to stockholders – Diluted	$	(200	)	$	(5,782	)	$	(786	)	$	(668	)	$	(3,208	)
	Basic net income (loss) per common share attributable to common stockholders	$	0.03		$	(0.06	)	$	(0.01	)	$	0		$	(0.03	)
	Diluted net income (loss) per common share attributable to common stockholders	$	0		$	(0.06	)	$	(0.01	)	$	0		$	(0.03	)

B_Summary_of_Significant_Accou1

B. Summary of Significant Accounting Policies - Net Income (Loss) Per Common Share (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Numerator:
Net income (loss)	($80)	($3,208)
Net income attributable to participating securities	0	0
Net income (loss) attributable to common stockholders - basic	-80	-3,208
Net income (loss)	-80	-3,208
Less gain (loss) on warrant liability for participating common warrants	0	0
Net income (loss) attributable to common stockholders - diluted	($80)	($3,208)
Denominator:
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - basic	134,667	106,554
Effect of potentially dilutive securities: Common stock warrants	0	0
Effect of potentially dilutive securities: Convertible preferred warrants	0	0
Effect of potentially dilutive securities: Convertible preferred stock	0	0
Effect of potentially dilutive securities: Common stock options	0	0
Effect of potentially dilutive securities: Non-participating common stock warrants	0	0
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - diluted	134,667	106,554
Basic net income (loss) per common share	$0	($0.03)
Diluted net income (loss) per common share	$0	($0.03)

C_Liquidity_Details_Narrative

C Liquidity (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
C Liquidity Details Narrative
Cash outflows from operations	$323	($2,970)
Net Income (loss)	-80	-3,208
Non-cash gain for decreases in valuation of warrants		($510)

D_Investments_Details_Narrativ

D. Investments (Details Narrative)	Sep. 30, 2014
D. Investments Details Narrative
Equity method investment ownership interest	35.00%

F_Stockholders_Equity_Warrants

F. Stockholders' Equity - Warrants (Details)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Number of Shares	16,029,627	17,879,627
$0.38
Number of Shares	50,000	50,000
Expiration Date	15-Apr	15-Apr
$0.50
Number of Shares	50,000	50,000
Expiration Date	16-May	16-May
$0.50
Number of Shares	50,000	50,000
Expiration Date	16-Jul	16-Jul
$1.00
Number of Shares	50,000	50,000
Expiration Date	16-Jul	16-Jul
$1.50
Number of Shares	50,000	50,000
Expiration Date	16-Jul	16-Jul
$2.00
Number of Shares	50,000	50,000
Expiration Date	16-Jul	16-Jul
$2.50
Number of Shares	50,000	50,000
Expiration Date	16-Jul	16-Jul
$0.40
Number of Shares	1,337,627	1,337,627
Expiration Date	17-Mar	17-Mar
$0.40
Number of Shares	325,000	325,000
Expiration Date	17-Apr	17-Apr
$0.26
Number of Shares	300,000	300,000
Expiration Date	17-Jun	17-Jun
$0.26
Number of Shares	50,000
Expiration Date	17-Jun
$0.35
Number of Shares	140,000	140,000
Expiration Date	17-Oct	17-Oct
$0.25
Number of Shares	12,285,000	13,085,000
Expiration Date	18-Feb	18-Feb
$0.25
Number of Shares	1,242,000	1,742,000
Expiration Date	18-Mar	18-Mar
$1.00
Number of Shares		125,000
Expiration Date		14-Jun
$0.60
Number of Shares		15,000
Expiration Date		14-Sep
$0.50
Number of Shares		100,000
Expiration Date		14-May
$0.50
Number of Shares		15,000
Expiration Date		14-Sep
$1.00
Number of Shares		100,000
Expiration Date		14-May
$1.50
Number of Shares		100,000
Expiration Date		14-May
$0.39
Number of Shares		20,000
Expiration Date		14-Sep
$0.51
Number of Shares		125,000
Expiration Date		14-Jun

F_Stockholders_Equity_Warrant_

F. Stockholders' Equity - Warrant Activity (Details 2) (Warrant [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Warrant [Member]
Number of Shares
Outstanding beginning balance	18,775,664	62,993,663
Granted	50,000	14,932,000
Exercised	-1,300,000	-59,149,999
Cancelled	-600,000	0
Forfeited	0	0
Outstanding ending balance	16,925,664	18,775,664
Exercisable	16,925,664
Exercise Price
Outstanding beginning balance	$0.29	$0.30
Granted	$0.26	$0.25
Exercised	$0.25	$0.01
Expired or Canceled	$0.86
Forfeited
Outstanding ending balance	$0.27	$0.29
Exercisable	$0.27
Remaining Contractual Term (in years)
Outstanding beginning balance	4 years 1 month 6 days	4 years 2 months 12 days
Granted		4 years 4 months 24 days
Outstanding ending balance	3 years 1 month 6 days	4 years 1 month 6 days
Exercisable	3 years 1 month 6 days
Aggregate Intrinsic Value
Outstanding beginning balance	$693,340	$5,344
Granted		444,810
Exercised	318,000	19,519,500
Outstanding ending balance	215,048	693,340
Exercisable	$215,048

G_StockBased_Compensation_Stoc

G. Stock-Based Compensation - Stock Option Activity (Details) (Employee Stock Option [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Employee Stock Option [Member]
Number of Shares
Outstanding beginning balance	11,214,898	9,473,661
Granted	775,000	3,070,000
Exercised
Cancelled	-393,307	-1,328,763
Forfeited
Outstanding ending balance	11,596,591	11,214,898
Exercisable	11,427,839
Exercise Price
Outstanding beginning balance	$0.52	$0.70
Granted	$0.26	$0.40
Exercised
Cancelled	$2.64	$1.46
Forfeited
Outstanding ending balance	$0.43	$0.52
Exercisable	$0.44
Remaining Contractual Term (in years)
Outstanding beginning balance	6 years 8 months 12 days	5 years 9 months 18 days
Granted	6 years 1 month 6 days	9 years 4 months 24 days
Outstanding ending balance	6 years 1 month 6 days	6 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding beginning balance	$2	$154
Outstanding ending balance	1	2
Exercisable	$1

G_StockBased_Compensation_Nonv

G. Stock-Based Compensation - Nonvested Options (Details 1) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
G. Stock-Based Compensation - Nonvested Options Details 1
Nonvested beginning	1,482,286	406,766
Granted	775,000	3,070,000
Vested	-2,088,534	-1,994,480
Forfeited	0	0
Nonvested ending	168,752	1,482,286
Weighted Average Grant-Date Fair Value, Nonvested beginning	$0	$0.26
Granted	$0.22	$0.37
Vested	$0.33	$0.34
Forfeited
Weighted Average Grant-Date Fair Value, Nonvested ending	$0.22	$0.37

G_StockBased_Compensation_Deta

G. Stock-Based Compensation - Details of stock options (Details 2) (USD $)	12 Months Ended
	Sep. 30, 2014
OptionsB Outstanding
Number Outstanding at September 30	11,596,591
Weighted Average Exercise Price	$0.43
OptionsB Exercisable
Number Exercisable at September 30	11,427,839
Weighted Average Exercise Price	$0.44
Weighted Average Remaining Contractual Life (inB years)	6 years 18 days
0.23-$0.30
OptionsB Outstanding
Number Outstanding at September 30	2,387,500
Weighted Average Exercise Price	$0.28
Weighted Average Remaining Contractual Life (inB years)	6 years 6 months 18 days
OptionsB Exercisable
Number Exercisable at September 30	2,218,748
Weighted Average Exercise Price	$0.28
Weighted Average Remaining Contractual Life (inB years)	6 years 4 months 2 days
0.31-$0.40
OptionsB Outstanding
Number Outstanding at September 30	6,501,500
Weighted Average Exercise Price	$0.39
Weighted Average Remaining Contractual Life (inB years)	6 years 9 months 25 days
OptionsB Exercisable
Number Exercisable at September 30	6,501,500
Weighted Average Exercise Price	$0.39
Weighted Average Remaining Contractual Life (inB years)	6 years 9 months 25 days
0.41-$0.50
OptionsB Outstanding
Number Outstanding at September 30	502,000
Weighted Average Exercise Price	$0.45
Weighted Average Remaining Contractual Life (inB years)	7 years 3 months
OptionsB Exercisable
Number Exercisable at September 30	502,000
Weighted Average Exercise Price	$0.45
Weighted Average Remaining Contractual Life (inB years)	7 years 3 months
0.51-$0.60
OptionsB Outstanding
Number Outstanding at September 30	963,750
Weighted Average Exercise Price	$0.59
Weighted Average Remaining Contractual Life (inB years)	4 years 7 months 20 days
OptionsB Exercisable
Number Exercisable at September 30	963,750
Weighted Average Exercise Price	$0.59
Weighted Average Remaining Contractual Life (inB years)	4 years 7 months 20 days
0.61-$0.70
OptionsB Outstanding
Number Outstanding at September 30	66,500
Weighted Average Exercise Price	$0.68
Weighted Average Remaining Contractual Life (inB years)	1 year 10 months 17 days
OptionsB Exercisable
Number Exercisable at September 30	66,500
Weighted Average Exercise Price	$0.68
Weighted Average Remaining Contractual Life (inB years)	1 year 10 months 17 days
0.71-$0.80
OptionsB Outstanding
Number Outstanding at September 30	382,250
Weighted Average Exercise Price	$0.75
Weighted Average Remaining Contractual Life (inB years)	2 years 7 months 28 days
OptionsB Exercisable
Number Exercisable at September 30	382,250
Weighted Average Exercise Price	$0.75
Weighted Average Remaining Contractual Life (inB years)	2 years 7 months 28 days
0.81-$0.90
OptionsB Outstanding
Number Outstanding at September 30	697,091
Weighted Average Exercise Price	$0.88
Weighted Average Remaining Contractual Life (inB years)	2 years 4 days
OptionsB Exercisable
Number Exercisable at September 30	697,091
Weighted Average Exercise Price	$0.88
Weighted Average Remaining Contractual Life (inB years)	2 years 4 days
0.91-$1.00
OptionsB Outstanding
Number Outstanding at September 30	44,500
Weighted Average Exercise Price	$0.94
Weighted Average Remaining Contractual Life (inB years)	11 months 26 days
OptionsB Exercisable
Number Exercisable at September 30	44,500
Weighted Average Exercise Price	$0.94
Weighted Average Remaining Contractual Life (inB years)	11 months 26 days
1.01-$1.45
OptionsB Outstanding
Number Outstanding at September 30	51,500
Weighted Average Exercise Price	$1.13
Weighted Average Remaining Contractual Life (inB years)	1 year 4 days
OptionsB Exercisable
Number Exercisable at September 30	51,500
Weighted Average Exercise Price	$1.13
Weighted Average Remaining Contractual Life (inB years)	1 year 4 days

G_StockBased_Compensation_Deta1

G. Stock-Based Compensation (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Notes to Financial Statements
Research and Development Expenses	$11	$20
General and Administrative Expenses	624	841
Total Stock-based compensation expense	$635	$861

G_StockBased_Compensation_Deta2

G. Stock-Based Compensation (Details 4)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Notes to Financial Statements
Dividend yield	0.00%	0.00%
Expected volatility	122.00%	156.00%
Risk-free interest rate	1.54%	0.86%
Expected term	5 years 3 months 7 days	5 years 3 months 7 days

G_StockBased_Compensation_Deta3

G. Stock-Based Compensation (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014
G. Stock-Based Compensation Details Narrative
Unrecognized compensation expense	$172,000
Period for recognition	5 months

H_Income_Taxes_Details

H. Income Taxes (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
H. Income Taxes Details
Accrued payroll related liabilities	$1,103	$915
Depreciation and amortization	704	823
State Taxes	-126	-121
Total deferred tax assets	1,681	1,617
Deferred tax liabilities	0	0
Valuation allowance for deferred assets	-1,681	-1,617
Net deferred tax asset	$0	$0

H_Income_Taxes_Details_1

H. Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
H. Income Taxes Details 1
Effective income tax rate	0.00%	0.00%
United States Federal income tax at statutory rate	($25)	($1,091)
State income taxes (net of federal benefit)	1	5
Warrant expense	0	173
Prior year deferred true up	-280	-1,684
Change in valuation reserves	96	-1,863
FIN 48	354	4,396
Other	-144	66
Provision for income taxes	$2	$2

H_Income_Taxes_Details_2

H. Income Taxes (Details 2) (USD $)	12 Months Ended
	Sep. 30, 2014
H. Income Taxes Tables
Unrecognized tax benefits at October 1, 2012	$4,397
Additions for tax positions related to current year	458
Additions/reductions for tax positions taken in prior years	4
Settlements	0
Lapse of Limitations	0
Unrecognized tax benefits at September 30, 2014	$4,859

J_Quarterly_Financial_Data_Det

J. Quarterly Financial Data (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Total revenue	$9,631	$3,928
Net income (loss)	-80	-3,208
Net income available to stockholders b Basic	-80	-3,208
Net income available to stockholders b Diluted	-80	-3,208
Basic net income (loss) per common share attributable to common stockholders	$0	($0.03)
Diluted net income (loss) per common share attributable to common stockholders	$0	($0.03)
First Quarter
Total revenue	793	1,342
Net income (loss)	-695	4,028
Net income available to stockholders b Basic	-695	2,049
Net income available to stockholders b Diluted	-695	-200
Basic net income (loss) per common share attributable to common stockholders	($0.01)	$0.03
Diluted net income (loss) per common share attributable to common stockholders	($0.01)	$0
Second Quarter
Total revenue	1,438	859
Net income (loss)	-437	-5,782
Net income available to stockholders b Basic	-437	-5,782
Net income available to stockholders b Diluted	-437	-5,782
Basic net income (loss) per common share attributable to common stockholders	$0	($0.06)
Diluted net income (loss) per common share attributable to common stockholders	$0	($0.06)
Third Quarter
Total revenue	4,983	844
Net income (loss)	1,576	-786
Net income available to stockholders b Basic	1,576	-786
Net income available to stockholders b Diluted	1,576	-786
Basic net income (loss) per common share attributable to common stockholders	$0.01	($0.01)
Diluted net income (loss) per common share attributable to common stockholders	$0.01	($0.01)
Fourth Quarter
Total revenue	2,417	883
Net income (loss)	-524	-668
Net income available to stockholders b Basic	-524	-668
Net income available to stockholders b Diluted	($524)	($668)
Basic net income (loss) per common share attributable to common stockholders	$0	$0
Diluted net income (loss) per common share attributable to common stockholders	$0	$0